爱尔眼科(300015) - 2016 Q3 - 季度业绩预告

Financial Performance - The net profit attributable to shareholders for the period from January 1 to September 30, 2016, is expected to be between RMB 44,800.48 million and RMB 48,384.51 million, representing a growth of 25%-35% compared to the previous year’s profit of RMB 35,840.38 million[3]. - For the third quarter (July to September 2016), the net profit attributable to shareholders is projected to be between RMB 18,760.96 million and RMB 20,324.37 million, compared to RMB 15,634.13 million in the same period last year[3]. Factors Influencing Profit - The increase in net profit is attributed to the continuous growth in demand in the ophthalmology market, expansion of the company's operational scale, and enhanced brand influence[5]. - The company anticipates a negative impact of approximately RMB 4 million from non-recurring gains and losses on net profit during this reporting period[6]. Financial Reporting - The financial data presented is based on preliminary estimates by the company's finance department, with detailed financial results to be disclosed in the Q3 2016 report[6].